PTC Therapeutics (NASDAQ:PTCT) Insider Neil Gregory Almstead Sells 23,749 Shares

Posted by Brian Himes on Jun 24th, 2026

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) insider Neil Gregory Almstead sold 23,749 shares of the company’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $80.90, for a total transaction of $1,921,294.10. Following the completion of the sale, the insider directly owned 60,137 shares of the company’s stock, valued at $4,865,083.30. The trade was a 28.31% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Neil Gregory Almstead also recently made the following trade(s):

On Wednesday, April 1st, Neil Gregory Almstead sold 52,003 shares of PTC Therapeutics stock. The stock was sold at an average price of $69.04, for a total transaction of $3,590,287.12.

PTC Therapeutics Stock Up 2.8%

PTC Therapeutics stock traded up $2.28 during mid-day trading on Wednesday, hitting $84.41. The company’s stock had a trading volume of 3,320,510 shares, compared to its average volume of 1,378,512. The stock has a market capitalization of $7.00 billion, a P/E ratio of -36.23, a P/E/G ratio of 3.72 and a beta of 0.56. PTC Therapeutics, Inc. has a twelve month low of $43.17 and a twelve month high of $87.50. The stock’s fifty day moving average price is $71.84 and its two-hundred day moving average price is $71.94.

PTC Therapeutics (NASDAQ:PTCT – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.42. PTC Therapeutics had a negative return on equity of 362.45% and a negative net margin of 22.58%.The business had revenue of $272.55 million during the quarter, compared to analyst estimates of $217.42 million. During the same period last year, the company posted $10.04 EPS. The company’s revenue was up 43.5% compared to the same quarter last year. Equities analysts expect that PTC Therapeutics, Inc. will post 0.78 earnings per share for the current year.

Wall Street Analyst Weigh In

PTCT has been the subject of several research analyst reports. Wells Fargo & Company upped their price target on shares of PTC Therapeutics from $86.00 to $95.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. TD Cowen upgraded PTC Therapeutics from a “hold” rating to a “buy” rating and increased their target price for the company from $75.00 to $90.00 in a report on Friday, May 8th. Truist Financial raised PTC Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. Raymond James Financial started coverage on PTC Therapeutics in a report on Friday, April 10th. They set an “outperform” rating and a $108.00 price target on the stock. Finally, Royal Bank Of Canada increased their price objective on PTC Therapeutics from $81.00 to $82.00 and gave the stock a “sector perform” rating in a research note on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $91.36.

Read Our Latest Research Report on PTCT

Institutional Trading of PTC Therapeutics

A number of institutional investors have recently bought and sold shares of PTCT. UMB Bank n.a. acquired a new position in PTC Therapeutics in the 4th quarter worth about $26,000. Optiver Holding B.V. increased its holdings in PTC Therapeutics by 96.5% in the third quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 249 shares during the last quarter. Comerica Bank raised its position in PTC Therapeutics by 868.5% during the third quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 469 shares in the last quarter. Salomon & Ludwin LLC acquired a new stake in PTC Therapeutics in the fourth quarter valued at approximately $41,000. Finally, IFP Advisors Inc grew its position in PTC Therapeutics by 68.1% in the third quarter. IFP Advisors Inc now owns 765 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 310 shares in the last quarter.

About PTC Therapeutics

(Get Free Report)

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.